{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:08Z","timestamp":1753891808011,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The anti-programmed cell death-1 (PD-1) antibody nivolumab has been shown to significantly prolong the survival of patients with unresectable advanced or recurrent gastric cancer (AGC). However, immune-related adverse events (irAEs), which show different profiles from those of cytotoxic agents or conventional molecular-targeted drugs including tyrosine kinase inhibitors, have been reported. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare autoimmune disorder with acute-onset, rheumatoid factor-negative, symmetric synovitis associated with limb edema observed in elderly persons. A case of RS3PE syndrome that developed after administration of nivolumab for advanced gastric cancer is reported. This is the first report of a case of RS3PE syndrome as an irAE caused by nivolumab in a patient with gastric cancer.<\/jats:p>","DOI":"10.3389\/fonc.2023.1260818","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T19:23:40Z","timestamp":1696533820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Hirofumi","family":"Ohmura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Uenomachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ayano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Niiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1985.03360190069027","article-title":"Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome","volume":"254","author":"McCarty","year":"1985","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2016.1192744","article-title":"Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome","volume":"27","author":"Origuchi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"B11","article-title":"More on remitting seronegative symmetrical synovitis with pitting edema as a paraneoplastic syndrome","volume":"25","author":"Cantini","year":"1998","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.003","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","volume":"47","author":"Gauci","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13840","article-title":"Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced Malignant melanoma","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.12.013","article-title":"Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during nivolumab therapy for non-small cell lung cancer: a case report","volume":"48","author":"Filetti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13256-018-1579-1","article-title":"Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report","volume":"12","author":"Ngo","year":"2018","journal-title":"J Med Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0810-1","article-title":"OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody","volume":"122","author":"Ohmura","year":"2020","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032995","article-title":"RS3PE syndrome presenting as vascular endothelial growth factor associated disorder","volume":"64","author":"Arima","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semarthrit.2008.11.006","article-title":"Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis","volume":"40","author":"Yao","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"B20","article-title":"Analysis of peripheral blood lymphocytes using flow cytometry in polymyalgia rheumatica, RS3PE and early rheumatoid arthritis","volume":"26","author":"Shimojima","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390719","article-title":"Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment","volume":"39","author":"Meliconi","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s7489","article-title":"Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica","volume":"4","author":"Yanai","year":"2009","journal-title":"Clin Interv Aging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11926-015-0525-0","article-title":"RS3PE: clinical and research development","volume":"17","author":"Li","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12854","article-title":"Remitting seronegative symmetrical synovitis with pitting edema associated with parvovirus B19 infection: two new cases and review of the comorbidities","volume":"54","author":"Drago","year":"2015","journal-title":"Int J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037390","article-title":"Remitting seronegative symmetrical synovitis with pitting oedema\/polymyalgia rheumatica after infection with Mycoplasma pneumoniae","volume":"64","author":"Matsuda","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jim-2020-001613","article-title":"Remitting seronegative symmetrical synovitis with pitting edema: a review","volume":"69","author":"Lakhmalla","year":"2021","journal-title":"J Investig Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1260818\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T19:23:44Z","timestamp":1696533824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1260818\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":26,"alternative-id":["10.3389\/fonc.2023.1260818"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1260818","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"article-number":"1260818"}}